EyePoint Pharmaceuticals (STU:PV3B) Total Inventories : €3.58 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is EyePoint Pharmaceuticals Total Inventories?

EyePoint Pharmaceuticals's total inventories for the quarter that ended in Dec. 2023 was €3.58 Mil. EyePoint Pharmaceuticals's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was €3.94 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. EyePoint Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was €4.58.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. EyePoint Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 was 392.47.

Inventory Turnover measures how fast the company turns over its inventory within a year. EyePoint Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.23.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. EyePoint Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.31.

EyePoint Pharmaceuticals Total Inventories Historical Data

The historical data trend for EyePoint Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Total Inventories Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

1.92

4.39

3.20

2.72

3.58

EyePoint Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories	Get a 7-Day Free Trial															2.72	3.80	3.93	4.29	3.58

EyePoint Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

EyePoint Pharmaceuticals (STU:PV3B) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

EyePoint Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(303.573	+	0.75 * 0.738	+	0.5 * 3.582	-	81.486
-	0	-	0)	/	49.0431
=	4.58

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

EyePoint Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	3.9355	/	0.915	*	365 / 4
	=	392.47

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

EyePoint Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	0.915	/	3.9355
	=	0.23

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

EyePoint Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	3.9355	/	12.864
	=	0.31

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

EyePoint Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (STU:PV3B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

EYPT:USA

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3B) Headlines

No Headlines